Search

everythinglearnresearchcommunity

for

Search:↓

Ixekizumab helps improve life quality, physical ability, and work performance in patients with psoriatic arthritis who haven't used biologic drugs before.

Personalized medicine in dermatology uses molecular biomarkers to improve diagnosis and treatment but needs further advancements for practical use.

Early treatment is key for permanent hair loss disorders, with options ranging from medications and phototherapy to immunomodulators and antibiotics, depending on severity and type.

Adalimumab significantly improved Hidradenitis Suppurativa and quality of life in two patients.

A girl with Crohn's disease developed hair loss due to her increased medication, a rare side effect seen in some children.

Hidradenitis Suppurativa has genetic links, with certain gene mutations more common in patients and a third of cases having a family history.

Hidradenitis Suppurativa is likely an autoinflammatory disease, and better understanding its causes could improve treatments.

In 2017, pediatric dermatology advanced with new treatments and insights into various skin conditions in children.

Treatment with biologic agents can significantly improve psoriasis symptoms, and blood biomarkers could potentially predict individual patient's response to treatment.

Adalimumab can cause complete hair loss in rare cases.

The issue concluded that various skin conditions have different effective treatments and factors influencing them.

Real-life dosing of biologics for plaque psoriasis often deviates from recommended guidelines, especially for high-need patients.

Biologic agents can be effective for rheumatic diseases but have risks like infections and require careful monitoring and patient information.

A multi-tiered treatment approach is crucial for managing hidradenitis suppurativa in patients with intellectual and developmental disabilities.

A multi-tiered treatment approach is crucial for managing hidradenitis suppurativa in patients with intellectual and developmental disorders.

Blocking interferon-gamma might help treat various autoimmune diseases.

New treatments for Alopecia Areata, like JAK inhibitors, show promise for hair regrowth and are likely to change future treatment approaches.

Topical drugs and near-infrared light therapy show potential for treating alopecia.

Immunosuppressive and anti-TNF therapies in IBD patients can increase the risk of skin cancer and cause various skin issues.

Ustekinumab might work for severe psoriasis, but more research is needed to be sure.

Treating hidradenitis suppurativa needs long-term care and teamwork among doctors, but there's a lack of strong guidance on how to do it.

Early treatment of acne is crucial to prevent scarring and psychological effects.

Tofacitinib may slow hair loss in scarring alopecias but is unlikely to regrow significant hair.

New drugs for Alzheimer's and rheumatoid arthritis advanced, a Zika vaccine is in development, and there were business deals in anesthesia and oncology.

Understanding drug interactions, side effects, and patient-specific factors is crucial for effective dermatological care.

The document emphasizes early detection and treatment of men's skin conditions and recommends protective measures and appropriate treatments for different age groups.

Social media can help compare the effectiveness and safety of new arthritis medications.

Some drugs used to treat immune conditions may cause different types of hair loss.

Patients with RASopathies are at risk for autoimmune disorders and should be routinely screened.

A new vaccine using a porous scaffold boosts immunity and protects against the flu better than traditional methods.